Emphasis is on long-term compounding in revolutionary technologies, strong moats, and waiting for dips rather than chasing. Key themes: Tesla as the “fastest horse” near-term for humanoid/robotics upside; patience on new listings and beaten-down assets.1. Intuitive Surgical (ISRG) – Healthcare RoboticsDescription: Leader in robotic-assisted surgery with ~80% market share via its Da Vinci Systems. High-margin, strong-moat business focused on precision surgery.
Current: ~$414/share, ~$146B market cap, 40-50x PE.
Thesis: Undervalued per conservative models (Guru Focus fair value $598, ~50% upside; Wall Street avg target $557, ~35% upside). Fundamentals intact despite recent breakdown. Speaker holds a small position and likes the robotics angle.
Buying Recommendation: Attractive in the low-to-mid $400s. Potential to double/triple down on further weakness (possible ATR support ~$380). Watch macro/elective surgery trends and competition (Medtronic, J&J). Good for patients seeking healthcare/robotics exposure.2. Tesla (TSLA) – EVs, Autonomy, Humanoids, EnergyDescription: Core plays in electric vehicles, Full Self-Driving/robotaxis, Optimus humanoid robots, and energy. Speaker sees massive tailwinds from high-margin products.
Thesis: Tesla is the likely dominant winner in humanoids (actuators, vertical integration). Optimus + robotaxis could drive enormous valuation (speaker references Musk’s $25T + $5T potential). Faster horse vs. SpaceX near-term; merger expected years out (2027+).
Buying Recommendation: Aggressive buying “hand over fist” under $400 recently (including leaps/synthetics). Hold core shares; use dips. Risk management: avoid excessive margin.3. SpaceX – Space Launch, Starlink, etc.Description: Leading space company (rockets, satellite internet, future ambitions). Recent IPO at ~$2.2T market cap.
Current: ~$169–$170/share (after-hours moves noted).
Entry/Timing: IPOs often dip in first 30 days due to unlocks/volatility. Wait for 20%+ drawdown (near $135–$141) as a line in the sand. DCA on aggressive dips after initial volatility settles. Indicators (e.g., 50-day MA) become reliable after ~50–200 trading days. Avoid chasing green candles.
Longer-term: High-conviction compounding asset. Sandbagged targets shared for millionaire scenarios (e.g., hundreds of shares depending on horizon). KAGAR ~35% suggested (adjust based on entry price).4. Solana (SOL) Ecosystem & ProxiesSOL Thesis: Superior fundamentals vs. Ethereum (4,000%+ more daily transactions, 550%+ more active users, cheaper/faster). Adoption growing but crypto sentiment weak. Hold for rebound driven by agents/adoption.
Solana Proxies (public companies holding SOL treasuries – trade at discounts to NAV of their SOL holdings): UPXI: ~44 cents on the dollar (biggest discount).
HSDT: ~65 cents.
DeFi Dev: ~62 cents.
Forward Industries: ~67 cents (holds more SOL ~7M).
Stake: Trading at premium – speaker suggests rotating out into deeper discounts.
Recommendation: These are leveraged SOL plays. When SOL rebounds, proxies move faster (but higher risk). Tiny positions typical due to volatility. Fundamentals strong but race-to-the-bottom in DeFi/Dex competition noted for related alts (e.g., ORCA, RAY, JUP – mostly hold as crumbs).
Other NotesHumanoids/Physical AI: Focus on the winner (Tesla) rather than deep value-chain suppliers (actuators ~60% of cost). Designer/integrator margins far superior to component makers. Many Chinese plays flagged as higher risk.
Risk Management: Balance risk/reward; sandbag projections; longer horizons amplify compounding. Margin use only for experienced investors with buffers.